|Bid||8.76 x 1800|
|Ask||9.17 x 1300|
|Day's range||8.36 - 9.12|
|52-week range||7.85 - 52.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.50|
Rebounding from the 16% slide that they experienced last week, shares of Zymergen (NASDAQ: ZY) are soaring today as investors learn of an insider's significant acquisition of the company's stock. As of 10:34 a.m. ET, shares of the synthetic-biology company's stock are up 8.5%, having given back some of the 13.8% gain they made earlier in the trading session. According to a recent filing, Flatley bought 100,000 shares of stock in a transaction valued at $1 million, bringing his total position to 144,789 shares.
LOS ANGELES, November 11, 2021--The Law Offices of Frank R. Cruz Announces Investigation of Zymergen Inc. (ZY) on Behalf of Investors
LOS ANGELES, November 10, 2021--Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announces that it has commenced an investigation of potential claims against the board of directors of Zymergen Inc. ("Zymergen" or the "Company") (NASDAQ: ZY) concerning whether the board of directors breached its fiduciary duties to Zymergen shareholders.